Every letter we have printed

Placement carries meaning. A mark beside a price reads as a claim about that product; the same mark in a footer reads as a claim about the company. Sellers know this and choose accordingly, and no rule anywhere governs the choice.

Pre-registration would cost nothing here. Say in advance which suppliers and which molecules will be purchased, then publish everything that comes back. It is the single reform that would make the difference between a testing programme and a collection of anecdotes.

A methodological plea. Publish the purchase date, the arrival date and the determination date for every blind result. Without all three, a poor figure cannot be attributed between manufacture, freight and storage, and every party will attribute it wherever suits them.

Blind means the analyst does not know the origin. It does not mean the analyst does not know the expected answer, and for a common molecule at a common strength they will. That is a second blinding nobody attempts and it is not obvious it can be attempted.

The strongest blind design I have seen anywhere involved a third party holding the purchase record, the laboratory receiving numbered tubes and the mapping opened only after all results were in. It is not expensive. It is simply organisation, and organisation is what this market lacks.

Blinding at the laboratory end is the easy half and the half everybody talks about. An analyst who does not know which supplier they are testing is protected against one bias and against none of the others in the chain.

Composition ratios from trials that included a structured activity component are quoted in discussions where no such component exists. The trial measured a package and the figure is read as a property of one element of it.

Where the substudy population volunteered for an additional scan, they are a self-selected subset of an already selected trial population. Two layers of selection, and every figure downstream inherits both.

Absolute and relative statements point in opposite directions here and both are true. Lean mass falls in absolute terms and the proportion of the body that is lean can rise. Choosing which to headline is an editorial decision and it should be made visibly.

Publishing the individual-level scatter rather than the group means would transform this literature. The means are compatible with several very different underlying distributions and the scatter would distinguish them immediately.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

Weight trajectories in the published trials flatten well before the study ends, and the curve shape is one of the most useful things a reader can be shown. Expectations set on the early gradient are set on a section of a curve that does not continue.

Escalating in response to a plateau is discussed as though the relationship between exposure and effect were linear beyond the studied range. It is not, in any published dose-response data I have seen, and the curve flattens there too.

You keep insisting on peptide content rather than purity when discussing dose certainty. I have looked at a dozen certificates from four different testing services and content is reported on perhaps a third of them. What are readers supposed to do with an absence?

The section on what the pharmacology does not tell us is the one I would keep if the rest were cut. Receptor occupancy does not predict a clinical response, and a mechanistic story that explains a result after the fact is not evidence that the result will generalise.

Receptor pharmacology tells you what can happen and outcome studies tell you what does. Presenting the first as though it settled the second is the commonest error in coverage of this class, and it is committed by people who know better.

Two methods are only orthogonal if the mechanisms are independent, and two reversed-phase columns from different vendors are not. We spent a year believing we had orthogonality because the selectivities differed a little, and we had nothing of the kind. The test is the mechanism, not the part number.

Mass spectrometric detection on the same chromatographic run gives you an orthogonality of a sort for nothing, because a co-eluting species of different mass will show up in the extracted trace even when the ultraviolet peak looks clean. The separation is not orthogonal but the detection is, and for the co-elution question that is what matters.

A small technical correction. You write that trifluoroacetic acid is used at around 0.1 per cent. In peptide work concentrations of 0.05 to 0.1 per cent are both common, and some methods run higher for particularly basic sequences. The figure reads as though it were a standard rather than a range.

On response factors: you say correction requires isolated impurity standards, which is true, but you might mention that charged aerosol and mass-based detection sidestep the problem by responding more uniformly. Neither is exotic any more.

The table showing what each method can detect is valuable but incomplete. You show no row for C-terminal truncation or N-terminal truncation as distinct phenomena. These are not rare, and they often elute differently depending on which end is missing. A generic gradient might resolve them; an improperly designed orthogonal method might not. The capability matrix should separate these cases.

Interference is a real problem for peptide samples in these assays, and a laboratory that does not report an inhibition or enhancement check has not established that the result is valid for that matrix.

A result on one vial from a lot is a result about that vial. Endotoxin contamination is frequently sporadic rather than uniform, which is precisely why pharmacopoeial sampling plans specify more than one unit.

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

I have worked in aseptic fill for nineteen years and your section on media fills understates one thing. The scale is not the hard part. Running the simulation with every intervention the real process contains — every stopper jam, every environmental sample, every gowning break — is the hard part, and a simulation that omits the interventions is theatre with a growth medium in it.

Splitting an interval changes the peak-to-trough ratio and not the average exposure, which is a distinction with real consequences and no supporting outcome data in this class.

Interval and half-life are related by arithmetic that is published for each compound in this class, and the discussion proceeds mostly without it. The accumulation ratio for a given interval is calculable and rarely calculated.

The claim that nobody has randomised escalation intervals is too strong. There are protocol amendments in several programmes that effectively created slower-titration cohorts, and some of those have been analysed post hoc.

As a prescribing pharmacist I would add one thing about re-titration. The commonest problem I see is not the resumption dose. It is that the patient has a pen left over at the old strength and uses it because it is in the fridge and it cost money. The clinical decision and the economic decision are not the same decision.

You describe the plateau as an energy-balance event and dismiss receptor desensitisation. Is there not a third possibility — that adherence quietly falls off at around a year and the plateau is partly a behavioural artefact of the trial rather than a physiological one?

What is missing from the evidence base is any comparison of holding strategies. We have trials of schedules and no trials of the discretion applied to them, so every statement about how long to hold is extrapolation. Saying so plainly would be an improvement on most of what is written.

Steady state is reached at different times for different compounds in this class, and holding decisions made before it is reached are being made on incomplete information about that step.

The four-week interval is not arbitrary and your article explains why better than the labels do. With a half-life of about a week, four weeks is roughly the time to steady state, so a shorter interval escalates onto a concentration that has not finished rising. That is the arithmetic, and it deserves to be quoted whenever the interval is questioned.

The population most at risk on this endpoint is the one least represented in the trials, which is a general feature of trial recruitment and a specific problem here. Extrapolating a bone result across age bands is not supportable.

The skeletal findings in the trial substudies are modest and the follow-up is short, which is a fair summary and an unsatisfying one. Where the honest answer is that the duration studied is shorter than the duration of interest, saying so is better than filling the gap.

The ratio everybody quotes was measured in a population with a mean age and a mean starting composition, and it is applied without adjustment to people well outside both. Every term in that extrapolation is doing work that the original authors would not endorse.

You write that no trial has measured strength. There are observational cohorts with grip strength data. Why do you insist on randomised measurement?

A note from a reader in a laboratory rather than a clinic. The technical material is accurate often enough that I now check my assumptions against it rather than the other way round.

Dehydration is the mechanism by which a manageable symptom becomes a consequential one, and it is worth naming as the link. It is also the point at which renal function becomes the concern rather than the gut.

Symptoms appearing long after a stable period are a different signal from symptoms at escalation, and the timing is genuinely informative. New symptoms in a settled period deserve their own assessment rather than being attributed to the agent by default. Nothing here is medical advice.